Investing.com - Bioventus (NASDAQ: BVS) reported first quarter EPS of $-0.070, $0.07 worse than the analyst estimate of $0.001. Revenue for the quarter came in at $129.45M versus the consensus estimate of $117.3M.
Guidance
Bioventus sees Q2 2024 EPS of $0.250-$0.330 versus the analyst consensus of $0.150.
Bioventus sees Q2 2024 revenue of $535.000M-$550.000M versus the analyst consensus of $528.100M.
Bioventus's stock price closed at $4.00. It is down -9.300% in the last 3 months and up 321.010% in the last 12 months.
Bioventus saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Bioventus's stock price’s past reactions to earnings here.
According to InvestingPro, Bioventus's Financial Health score is "fair performance".
Check out Bioventus's recent earnings performance, and Bioventus's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar